Why Is Intellia Therapeutics Stock Trading Lower On Friday?
On Thursday, Intellia Therapeutics Inc (NASDAQ: NTLA ) outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z .
These therapies target hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis, respectively.
Intellia prioritized NTLA-2002 and nex-z while discontinuing the NTLA-3001 program and other early-stage initiatives.
The reorganization will result in a 27% workforce reduction and a projected $8 million restructuring charge in early 2025.
Intellia ended the fourth quarter of 2024 with approximately $862 million in cash, cash equivalents and investments.
Intellia ended 2024 with $862 million in cash and investments, projecting a cash runway through the first half of 2027, bolstered by anticipated cost savings from its reorganization.
Pipeline Progress and Financial Standing
2025 Milestones and Commercial Plans
Price Action: NTLA stock is down 12.7% at $10.49 at last check Friday.